Abner Herrman & Brock LLC Brainstorm Cell Therapeutics Inc. Transaction History

Abner Herrman & Brock LLC

  • $801 Million
  • Q1 2024

A detailed history of Abner Herrman & Brock LLC transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Abner Herrman & Brock LLC holds 145,500 shares of BCLI stock, worth $49,470. This represents 0.01% of its overall portfolio holdings.

Number of Shares
145,500
Previous 145,500 -0.0%
Holding current value
$49,470
Previous $40,000 105.0%
% of portfolio
0.01%
Previous 0.01%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 10, 2023
SELL
$0.2 - $2.08 $26,900 - $279,760
-134,500 Reduced 48.04%
145,500 $29,000
Q3 2022

Oct 06, 2022
BUY
$2.55 - $4.3 $38,250 - $64,500
15,000 Added 5.66%
280,000 $1.24 Million
Q1 2022

Apr 07, 2022
SELL
$2.92 - $4.19 $680,360 - $976,270
-233,000 Closed
0 $0
Q4 2021

Jan 13, 2022
BUY
$2.81 - $4.23 $78,680 - $118,440
28,000 Added 13.66%
233,000 $932,000
Q3 2021

Oct 06, 2021
SELL
$3.14 - $4.09 $114,610 - $149,285
-36,500 Reduced 15.11%
205,000 $676,000
Q4 2020

Jan 12, 2021
BUY
$3.99 - $17.73 $3,990 - $17,730
1,000 Added 0.42%
241,500 $1.09 Million
Q3 2020

Oct 08, 2020
BUY
$11.19 - $16.92 $16,785 - $25,380
1,500 Added 0.63%
240,500 $4.07 Million
Q2 2020

Jul 10, 2020
BUY
$4.42 - $12.66 $808,639 - $2.32 Million
182,950 Added 326.4%
239,000 $2.68 Million
Q1 2020

Apr 09, 2020
BUY
$4.01 - $8.88 $224,760 - $497,724
56,050 New
56,050 $260,000

Others Institutions Holding BCLI

# of Institutions
52
Shares Held
4.09M
Call Options Held
63.2K
Put Options Held
800
View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

BCLI Quotes by TradingView
  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $12.4M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Abner Herrman & Brock LLC Portfolio

Follow Abner Herrman & Brock LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abner Herrman & Brock LLC, based on Form 13F filings with the SEC.

News

Stay updated on Abner Herrman & Brock LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email